Search articles, concepts, and chapters
Section II · Clinical Forms
Shields' Textbook of Glaucoma, 6th edition
Showing 1–20 of 4,354 articles
Loukovaara Sirpa, Haukka Jari
This study found that postmenopausal hormone replacement therapy, particularly estrogen-only, was associated with an increased risk of developing glaucoma in women over 50.
Elhusseiny Abdelrahman M, Abboud Ibrahim, Almobayed Amr et al.
This study found chronic PDE-5 inhibitor use was associated with a lower risk of developing glaucoma suspect status or open-angle glaucoma in men, suggesting a potential protective effect.
Ntonti Panagiota, Coleman Anne L, Wilson Masao Roy et al.
This 12-year study identified high IOP, pseudoexfoliation, family history, and heart attack history as key risk factors for developing open-angle glaucoma, while increased sleep and alcohol were protective.
Solmaz Nilgun, Kutucu E Ece Oskan, Uysal Omer et al.
Bao Qing, Zheng Yan, Zeng Wen et al.
Mihalache Andrew, Huang Ryan S, Balas Michael et al.
Zhou Lin, Zhao Chenzhu, Li Dongfeng et al.
This study established normative wide-field retinal and choroidal thickness in Chinese children, finding distinct patterns influenced by age, myopia, and other ocular parameters, aiding early disease detection and monitoring.
Martinez-de-la-Casa Jose, Stalmans Ingeborg, Abegão-Pinto Luís et al.
Li Zihan, Pan Zhe, Huang Yu et al.
This study found that smoking is associated with thinner retinal ganglion cell and photoreceptor layers, suggesting smoking may contribute to optic nerve damage or age-related macular degeneration.
Tan Siyi, Li Dongjun, Liu Dianfeng et al.
AS-OCT showed Berger's space is more visible in acute angle closure and younger eyes, indicating its potential role in understanding PACD mechanisms and risk factors.
Busza Anna M, Lyons Clayton E, Hamzeh Nikoo et al.
This review found adult macular vessel density declines with age, while pediatric associations vary, highlighting age's importance for interpreting OCT-A metrics.
Clark Robert A, Wong Rupa K
This study found that while axial length (AL) thresholds identify very long eyes at high retinal risk, spherical equivalent refraction (SER) better predicts cataract, glaucoma, and general myopic pathology, suggesting SER should be the primary monitoring metric.
Abdelaal Abdelaziz, Abu Serhan Hashem, Alsaadi Mustafa et al.
This meta-analysis found metformin use might modestly reduce glaucoma risk, especially in time-to-event analyses, suggesting a potential preventative strategy for this irreversible blindness.
Sheibani Kourosh, Bayat Kia, Rajavi Zhale et al.
This review found preterm birth, even without ROP, causes persistent ophthalmic changes like refractive errors, strabismus, and structural differences. Long-term surveillance and early intervention are crucial.
Abboud Ibrahim, Fam Anthony, Almobayed Amr et al.
This study found pseudoexfoliation glaucoma (PXG) significantly increases the risk of central serous chorioretinopathy (CSCR) compared to primary open-angle glaucoma (POAG), suggesting shared posterior segment vascular susceptibility.
Saadi Wid, Bro Tomas, Sagerfors Susanna
This study found threshold perimetry (≥10dB within 20°) can predict driver's license visual field eligibility (Swedish/Norwegian standards) with good sensitivity. More people meet the current Swedish standard than the former.
Banerjee Seema, Mihailovic Aleksandra, Lee Moon Jeong et al.
This study found better home lighting, but not home hazards, was linked to less difficulty with daily tasks in glaucoma patients, suggesting lighting improvements can enhance function.
Vicente-Antolín Marta, González-López Julio José, Pardiñas Baron Nieves et al.
Iberian ocular syphilis frequently affects the posterior segment, with most patients achieving good visual and serological outcomes with standard treatment, emphasizing early diagnosis in high-risk groups.
Jiang Zixuan, Ouyang Jiamin, Yi Zhen et al.
This study found *RP1L1* variants cause most Chinese occult maculopathy cases, often with bilateral OCT changes. Genetic testing and mfERG are crucial for diagnosis and management, helping differentiate etiologies.
Nevrov Denis, O'Riordan Matthew, Fadlelseed Huda et al.
This study of six Irish pediatric uveal melanoma cases (2010-2024) found it extremely rare with favorable outcomes. Early diagnosis and treatment are crucial, highlighting the need for international data and molecular profiling.
The use of any postmenopausal hormonal replacement therapy (HRT) was associated with an increased risk for the development of glaucoma in 6576 postmenopausal women aged ≥50 years in Finland, after adjustment for confounding factors.
In postmenopausal women aged ≥50 years in Finland, estrogen-only hormonal replacement therapy (HRT) users had an increased risk of glaucoma (adjusted OR, 1.33 [95% CI, 1.17-1.52]) in a nested-case-control study involving 1096 cases and 5480 age-matched controls.
In postmenopausal women aged ≥50 years in Finland, progestogen-only hormonal replacement therapy (HRT) users had an increased risk of glaucoma (adjusted OR, 1.25 [95% CI, 1.02-1.53]) in a nested-case-control study involving 1096 cases and 5480 age-matched controls.
In postmenopausal women aged ≥50 years in Finland, combined estrogen-progesterone hormonal replacement therapy (HRT) users had an increased risk of glaucoma (adjusted OR, 1.19 [95% CI, 1.01-1.39]) in a nested-case-control study involving 1096 cases and 5480 age-matched controls.
In the primary open-angle glaucoma (POAG) subgroup of postmenopausal women aged ≥50 years in Finland, estrogen-only hormonal replacement therapy (HRT) users showed a significant increased risk (adjusted OR, 1.31 [95% CI, 1.10-1.56]) in a nested-case-control study involving 1096 cases and 5480 age-matched controls.
In a multicenter, retrospective cohort study of male adults aged ≥40 years with erectile dysfunction, the development of glaucoma suspect (GS) status was less frequent among phosphodiesterase type-5 inhibitor (PDE-5i) users at 1 year (6.49% vs 9.73%, p<0.01), 2 years (9.27% vs 10.86%, p<0.01), and 3 years (11.17% vs 12.06%, p=0.01) after propensity score matching.
In a multicenter, retrospective cohort study of male adults aged ≥40 years with erectile dysfunction, the development of open-angle glaucoma (OAG) was less frequent among phosphodiesterase type-5 inhibitor (PDE-5i) users at 1 year (2.13% vs 3.22%, p<0.01), 2 years (3.00% vs 3.80%, p<0.01), and 3 years (3.88% vs 4.28%, p=0.04) after propensity score matching.
Cox proportional models in a multicenter, retrospective cohort study of male adults aged ≥40 years with erectile dysfunction demonstrated reduced hazards for glaucoma suspect (GS) at 1 year (aHR 0.78; 95% CI, 0.75-0.81; p<0.01), 2 years (0.89; 0.86-0.93; p<0.01), and 3 years (0.94; 0.90-0.97; p=0.01) with phosphodiesterase type-5 inhibitor (PDE-5i) use.
Cox proportional models in a multicenter, retrospective cohort study of male adults aged ≥40 years with erectile dysfunction demonstrated reduced hazards for open-angle glaucoma (OAG) at 1 year (aHR 0.76; 95% CI, 0.71-0.81; p<0.01), 2 years (0.79; 0.75-0.83; p<0.01), and 3 years (0.84; 0.79-0.88; p=0.01) with phosphodiesterase type-5 inhibitor (PDE-5i) use.
Chronic phosphodiesterase type-5 inhibitor (PDE-5i) use was associated with a lower hazard of developing glaucoma suspect (GS) and open-angle glaucoma (OAG) over 1-, 2-, and 3-years of follow-up in men with erectile dysfunction.
Data for 55 patients (median [IQR] age at diagnosis for 45 patients, 24 [8-51] years; 33 male [67%]) from 37 families with ACO2 variants were compiled in a retrospective case series.
In a prospective-longitudinal population-based study of 826 elderly white subjects, baseline pseudoexfoliation (PEX) was associated with incident open-angle glaucoma (p=0.002).